



## First project award issued under Rapid Response Partnership Vehicle

Summerville, SC– May 15, 2024

The Rapid Response Partnership Vehicle (RRPV) Consortium is proud to announce the inaugural award made under the newly established Other Transaction Agreement with the [Biomedical Advanced Research and Development Authority](#) (BARDA) funded under Project NextGen, an initiative to advance vaccines, therapeutics, and enabling technologies to enhance preparedness for COVID-19 now and in the future. This milestone comes seven months after the formation of the RRPV Consortium in September 2023.

The first project award was made to [Allucent](#) for its groundbreaking initiative, *REimagining Measurements and Operations of Translational Endpoints (REMOTE)*, supporting the RRPV RPP-24-04-HomeFocus solicitation. The project award, valued at \$25.5 million, will support the planning and execution of a post-marketing decentralized clinical trial (DCT) with an FDA licensed COVID-19 vaccine.

The study will also evaluate the feasibility of home-focused DCT approaches, for example self-collection and shipping of clinical samples; electronic symptom reporting; and the use of wearable devices to monitor physiological symptoms.

DCTs have the potential to improve data collection from a larger and more diverse patient population when evaluating COVID-19 vaccines for correlates of protection. This project aims to revolutionize the way translational endpoints in clinical trials are measured and collected, to advance medical countermeasure (MCM) development.

"This award aims to foster collaboration and innovation within the MCM ecosystem, and we are excited to support this decentralized clinical trial to reduce barriers to participation and improve accessibility," said Mike Stebbins Ph.D., VP for Medical & Threat Countermeasures at ATI. "By harnessing the expertise of industry partners like Allucent, the RRPV is poised to make significant strides in addressing critical public health challenges."

For more information about the RRPV program and upcoming opportunities, please visit [rrpv.org](http://rrpv.org).

*The views expressed in this news release/article are those of the authors and may not reflect the official policy or position of the Department of Health and Human Services, Administration for Strategic Preparedness and Response or BARDA.*

### **About the Rapid Response Partnership Vehicle**

The RRPV is a new, 10-year, multi-purpose acquisition vehicle designed to support medical countermeasures, such as vaccines, therapeutics, and medical technology products from early-

stage development through advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The RRPV is managed by [Advanced Technology International](#).